THERACRYF PLC — AGM Information 2020

Jun 19, 2020

National Storage Mechanism | Additional information

RNS Number : 4115Q

Evgen Pharma PLC

19 June 2020

Evgen Pharma plc

(the "Company")

Notice of AGM

Evgen Pharma plc (AIM: EVG), the clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces it will hold its Annual General Meeting ("AGM") on Thursday, 16 July 2020 at 2pm.

Under the current UK Government guidance on social distancing and prohibiting public gatherings, it will not be possible for shareholders to attend the AGM in person. The meeting will take place via a conference call facility and entry will be restricted to shareholders only. To register for the dial in details, interested parties must provide their name as on the shareholder register or self-declare if the shares are held in a nominee account in order to be admitted as a guest.

For more information, please contact Walbrook PR by emailing [email protected] with the relevant information.

A copy of the AGM notice and proxy form will be posted to shareholders today.

Enquiries:

Evgen Pharma plc www.evgen.com		via Walbrook
Barry Clare, Chairman
Richard Moulson, CFO
finnCap www.finncap.com		+44 (0)20 7220 0500
Geoff Nash / Teddy Whiley (Corporate Finance)
Alice Lane (ECM)
Walbrook PR	+44 (0)20 7933 87870 or [email protected]
Paul McManus / Anna Dunphy		+44 (0)7980 541 893 / +44 (0)7876 741 001

About Evgen Pharma plc 

Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

Clinical data from the Company's open-label Phase II STEM trial has shown that SFX-01 can halt the growth of progressing tumours in patients with oestrogen-positive (ER+) metastatic breast cancer, and in some cases significantly shrink the tumour, whilst causing very few side effects.

The Company commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool.  It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.  

For further information, please visit: www.evgen.com 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

NOAEADKPFEFEEFA